News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB) - Minapharm/Rhein Minapharm Biogenetics SAE: Approval for a Phase II Clinical Trial with Elafin in Kidney Transplantation


12/10/2008 10:04:58 AM

IRVINE, Calif. & KIEL, Germany & CAIRO, Egypt--(BUSINESS WIRE)--Proteo, Inc. (OTCBB: PTEO; Frankfurt Freiverkehr: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG together with Minapharm Pharmaceuticals SAE (Cairo and Alexandria Stock Exchange: MIPH) and its subsidiary Rhein Minapharm Biogenetics SAE announced today that the responsible authority in Cairo has granted approval for a Phase II clinical trial to study the efficacy of Elafin on kidney transplant patients.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES